Plain-English translation of NCT04114136 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Melanoma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether adding or —two medications that affect how cells use energy—can make anti-PD-1 immunotherapy work better for people with advanced solid tumors like melanoma, lung cancer, liver cancer, and others. The idea is that these added medications may help create a better environment inside the tumor for immune cells to do their job, making the immunotherapy more effective.
Even though immunotherapy has helped many cancer patients, it doesn't work for everyone—some tumors develop ways to hide from the immune system. This trial is exploring whether combining the medication with drugs that change how tumors consume oxygen might overcome this resistance and help more patients benefit from treatment.
You likely qualify if…
You likely don't qualify if…
You will have a tumor biopsy before starting treatment, then be randomly assigned to one of three groups: immunotherapy alone, immunotherapy plus (a pill taken twice daily), or immunotherapy plus (a pill taken once daily). You'll receive your immunotherapy infusion every 3 to 4 weeks at the clinic. After 5 weeks, you'll have another biopsy to see how the treatment is affecting your tumor. If you respond well, you'll continue treatment for up to 2 years or until your disease progresses or side effects become unacceptable.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States